Having trouble accessing articles? Reset your cache.

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

Sue Desmond-Hellmann is stepping down after five years as CEO of the Bill & Melinda Gates Foundation. Before joining the foundation, she spent 14 years at Genentech Inc., where she helped develop cancer drugs Herceptin trastuzumab and Avastin bevacizumab. She then served as the first female chancellor of the University of California at San Francisco in 2009-14. Mark Suzman, the foundation's chief strategy

Read the full 634 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers